Alyftrek
Payments companies reported to CMS as associated with Alyftrek. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Alyftrek, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Alyftrek
These are the largest totals companies reported as associated with Alyftrek. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Patricia Eshaghian | Los Angeles, CA | Pulmonary Disease | $14,645.38 |
| Patricia Walker | New York, NY | Pulmonary Disease | $8,739.96 |
| Joan Decelie-Germana | Great Neck, NY | Pediatrics | $7,076.33 |
| John Dickinson | Omaha, NE | Pulmonary Disease | $6,512.12 |
| Anju Singhal | Falls Church, VA | Critical Care Medicine (Internal Medicine) | $6,119.30 |
| Jonathan Spahr | Philadelphia, PA | Pediatric Pulmonology | $5,309.72 |
| Gregory Sawicki | Boston, MA | Pediatric Pulmonology | $5,015.10 |
| Richard Belkin | Santa Barbara, CA | Pulmonary Disease | $4,968.63 |
| Kate Powers | Albany, NY | Pediatrics | $4,901.52 |
| Danielle Goetz | Buffalo, NY | Pediatric Pulmonology | $3,843.00 |
Prescribed Alyftrek?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.